Co-Diagnostics Inc. (CODX)
0.80
0.02 (3.17%)
At close: Jan 17, 2025, 3:59 PM
0.77
-3.11%
After-hours Jan 17, 2025, 07:42 PM EST
undefined% (undefined)
| Bid | 0.77 |
| Market Cap | 25.38M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -1.38 |
| PE Ratio (ttm) | -0.58 |
| Forward PE | n/a |
| Analyst | Hold |
| Ask | 0.8 |
| Volume | 73,035 |
| Avg. Volume (20D) | 189,872 |
| Open | 0.78 |
| Previous Close | 0.78 |
| Day's Range | 0.76 - 0.80 |
| 52-Week Range | 0.67 - 2.23 |
| Beta | undefined |
About CODX
Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. It offers polymerase chain reaction (PCR) diagnostic tests for COVID-19, tuberculosis, hepatitis B and C, human papilloma virus, malaria, chikungunya, dengue, and the zika virus; three multiplexed tests to ...
Industry Medical - Devices
Sector Healthcare
IPO Date Jul 12, 2017
Employees 155
Stock Exchange NASDAQ
Ticker Symbol CODX
Website https://www.codiagnostics.com
Analyst Forecast
According to 1 analyst ratings, the average rating for CODX stock is "Hold." The 12-month stock price forecast is $1.5, which is an increase of 88.68% from the latest price.
Buy 0.00%
Hold 100.00%
Sell 0.00%
Next Earnings Release
Co-Diagnostics Inc. is scheduled to release its earnings on Mar 13, 2025,
during market hours.
Analysts project revenue of $375.00K, reflecting a -89.45% YoY shrinking and earnings per share of -0.34, making a -32.00% decrease YoY.
Analysts project revenue of $375.00K, reflecting a -89.45% YoY shrinking and earnings per share of -0.34, making a -32.00% decrease YoY.
4 months ago
+7.2%
Co-Diagnostics shares are trading higher after the...
Unlock content with
Pro Subscription
5 months ago
+12.9%
Co-Diagnostics shares are trading higher after the CDC announced free at home Covid 19 test delivery programs will reopen in late September.
